The prevalence of alpha-1 antitrypsin deficiency in Ireland

<p>Abstract</p> <p>Background</p> <p>Alpha-1 antitrypsin deficiency (AATD) results from mutations in the SERPINA1 gene and classically presents with early-onset emphysema and liver disease. The most common mutation presenting with clinical evidence is the Z mutation, wh...

Full description

Bibliographic Details
Main Authors: Morris Valerie B, Dimitrov Borislav D, O'Brien Geraldine, Kelleher Dermot P, McPartlin Joseph, Floyd Olwen, O'Connor Catherine A, Carroll Tomás P, Taggart Clifford C, McElvaney Noel G
Format: Article
Language:English
Published: BMC 2011-07-01
Series:Respiratory Research
Online Access:http://respiratory-research.com/content/12/1/91
id doaj-a7f5e10760d04bd4b05fc6d1492048dd
record_format Article
spelling doaj-a7f5e10760d04bd4b05fc6d1492048dd2020-11-24T22:16:06ZengBMCRespiratory Research1465-99212011-07-011219110.1186/1465-9921-12-91The prevalence of alpha-1 antitrypsin deficiency in IrelandMorris Valerie BDimitrov Borislav DO'Brien GeraldineKelleher Dermot PMcPartlin JosephFloyd OlwenO'Connor Catherine ACarroll Tomás PTaggart Clifford CMcElvaney Noel G<p>Abstract</p> <p>Background</p> <p>Alpha-1 antitrypsin deficiency (AATD) results from mutations in the SERPINA1 gene and classically presents with early-onset emphysema and liver disease. The most common mutation presenting with clinical evidence is the Z mutation, while the S mutation is associated with a milder plasma deficiency. AATD is an under-diagnosed condition and the World Health Organisation recommends targeted detection programmes for AATD in patients with chronic obstructive pulmonary disease (COPD), non-responsive asthma, cryptogenic liver disease and first degree relatives of known AATD patients.</p> <p>Methods</p> <p>We present data from the first 3,000 individuals screened following ATS/ERS guidelines as part of the Irish National Targeted Detection Programme (INTDP). We also investigated a DNA collection of 1,100 individuals randomly sampled from the general population. Serum and DNA was collected from both groups and mutations in the SERPINA1 gene detected by phenotyping or genotyping.</p> <p>Results</p> <p>The Irish National Targeted Detection Programme identified 42 ZZ, 44 SZ, 14 SS, 430 MZ, 263 MS, 20 IX and 2 rare mutations. Analysis of 1,100 randomly selected individuals identified 113 MS, 46 MZ, 2 SS and 2 SZ genotypes.</p> <p>Conclusion</p> <p>Our findings demonstrate that AATD in Ireland is more prevalent than previously estimated with Z and S allele frequencies among the highest in the world. Furthermore, our targeted detection programme enriched the population of those carrying the Z but not the S allele, suggesting the Z allele is more important in the pathogenesis of those conditions targeted by the detection programme.</p> http://respiratory-research.com/content/12/1/91
collection DOAJ
language English
format Article
sources DOAJ
author Morris Valerie B
Dimitrov Borislav D
O'Brien Geraldine
Kelleher Dermot P
McPartlin Joseph
Floyd Olwen
O'Connor Catherine A
Carroll Tomás P
Taggart Clifford C
McElvaney Noel G
spellingShingle Morris Valerie B
Dimitrov Borislav D
O'Brien Geraldine
Kelleher Dermot P
McPartlin Joseph
Floyd Olwen
O'Connor Catherine A
Carroll Tomás P
Taggart Clifford C
McElvaney Noel G
The prevalence of alpha-1 antitrypsin deficiency in Ireland
Respiratory Research
author_facet Morris Valerie B
Dimitrov Borislav D
O'Brien Geraldine
Kelleher Dermot P
McPartlin Joseph
Floyd Olwen
O'Connor Catherine A
Carroll Tomás P
Taggart Clifford C
McElvaney Noel G
author_sort Morris Valerie B
title The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_short The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_full The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_fullStr The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_full_unstemmed The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_sort prevalence of alpha-1 antitrypsin deficiency in ireland
publisher BMC
series Respiratory Research
issn 1465-9921
publishDate 2011-07-01
description <p>Abstract</p> <p>Background</p> <p>Alpha-1 antitrypsin deficiency (AATD) results from mutations in the SERPINA1 gene and classically presents with early-onset emphysema and liver disease. The most common mutation presenting with clinical evidence is the Z mutation, while the S mutation is associated with a milder plasma deficiency. AATD is an under-diagnosed condition and the World Health Organisation recommends targeted detection programmes for AATD in patients with chronic obstructive pulmonary disease (COPD), non-responsive asthma, cryptogenic liver disease and first degree relatives of known AATD patients.</p> <p>Methods</p> <p>We present data from the first 3,000 individuals screened following ATS/ERS guidelines as part of the Irish National Targeted Detection Programme (INTDP). We also investigated a DNA collection of 1,100 individuals randomly sampled from the general population. Serum and DNA was collected from both groups and mutations in the SERPINA1 gene detected by phenotyping or genotyping.</p> <p>Results</p> <p>The Irish National Targeted Detection Programme identified 42 ZZ, 44 SZ, 14 SS, 430 MZ, 263 MS, 20 IX and 2 rare mutations. Analysis of 1,100 randomly selected individuals identified 113 MS, 46 MZ, 2 SS and 2 SZ genotypes.</p> <p>Conclusion</p> <p>Our findings demonstrate that AATD in Ireland is more prevalent than previously estimated with Z and S allele frequencies among the highest in the world. Furthermore, our targeted detection programme enriched the population of those carrying the Z but not the S allele, suggesting the Z allele is more important in the pathogenesis of those conditions targeted by the detection programme.</p>
url http://respiratory-research.com/content/12/1/91
work_keys_str_mv AT morrisvalerieb theprevalenceofalpha1antitrypsindeficiencyinireland
AT dimitrovborislavd theprevalenceofalpha1antitrypsindeficiencyinireland
AT obriengeraldine theprevalenceofalpha1antitrypsindeficiencyinireland
AT kelleherdermotp theprevalenceofalpha1antitrypsindeficiencyinireland
AT mcpartlinjoseph theprevalenceofalpha1antitrypsindeficiencyinireland
AT floydolwen theprevalenceofalpha1antitrypsindeficiencyinireland
AT oconnorcatherinea theprevalenceofalpha1antitrypsindeficiencyinireland
AT carrolltomasp theprevalenceofalpha1antitrypsindeficiencyinireland
AT taggartcliffordc theprevalenceofalpha1antitrypsindeficiencyinireland
AT mcelvaneynoelg theprevalenceofalpha1antitrypsindeficiencyinireland
AT morrisvalerieb prevalenceofalpha1antitrypsindeficiencyinireland
AT dimitrovborislavd prevalenceofalpha1antitrypsindeficiencyinireland
AT obriengeraldine prevalenceofalpha1antitrypsindeficiencyinireland
AT kelleherdermotp prevalenceofalpha1antitrypsindeficiencyinireland
AT mcpartlinjoseph prevalenceofalpha1antitrypsindeficiencyinireland
AT floydolwen prevalenceofalpha1antitrypsindeficiencyinireland
AT oconnorcatherinea prevalenceofalpha1antitrypsindeficiencyinireland
AT carrolltomasp prevalenceofalpha1antitrypsindeficiencyinireland
AT taggartcliffordc prevalenceofalpha1antitrypsindeficiencyinireland
AT mcelvaneynoelg prevalenceofalpha1antitrypsindeficiencyinireland
_version_ 1725791295580930048